Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Sees Large Decline in Short Interest

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) was the target of a large drop in short interest in the month of November. As of November 30th, there was short interest totalling 1,230,000 shares, a drop of 6.1% from the November 15th total of 1,310,000 shares. Approximately 3.8% of the shares of the stock are short sold. Based on an average daily trading volume, of 712,600 shares, the days-to-cover ratio is currently 1.7 days.

Institutional Investors Weigh In On Werewolf Therapeutics

A number of hedge funds have recently added to or reduced their stakes in HOWL. Millennium Management LLC grew its stake in shares of Werewolf Therapeutics by 96.4% during the second quarter. Millennium Management LLC now owns 1,110,298 shares of the company’s stock valued at $2,709,000 after purchasing an additional 544,881 shares during the last quarter. Renaissance Technologies LLC boosted its position in Werewolf Therapeutics by 103.1% in the 2nd quarter. Renaissance Technologies LLC now owns 171,000 shares of the company’s stock valued at $417,000 after buying an additional 86,800 shares during the last quarter. Walleye Capital LLC increased its stake in shares of Werewolf Therapeutics by 10.7% in the 3rd quarter. Walleye Capital LLC now owns 108,968 shares of the company’s stock valued at $231,000 after buying an additional 10,528 shares during the period. SG Americas Securities LLC bought a new stake in shares of Werewolf Therapeutics during the third quarter worth $29,000. Finally, Rhumbline Advisers acquired a new position in shares of Werewolf Therapeutics during the second quarter valued at $79,000. Institutional investors own 64.84% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of Werewolf Therapeutics in a research report on Tuesday, November 19th.

Werewolf Therapeutics Price Performance

Werewolf Therapeutics stock opened at $1.64 on Wednesday. The business’s fifty day moving average is $2.13 and its two-hundred day moving average is $2.32. The company has a debt-to-equity ratio of 0.29, a quick ratio of 10.10 and a current ratio of 10.10. The firm has a market cap of $73.08 million, a P/E ratio of -1.07 and a beta of 0.30. Werewolf Therapeutics has a 52 week low of $1.58 and a 52 week high of $8.19.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.